
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): March 31, 2025

HILLENBRAND, INC.
(Exact name of registrant as specified in its charter)

Indiana
(State or other jurisdiction of incorporation)

1-33794
(Commission
File Number)

26-1342272
(IRS Employer
Identification No.)

One Batesville Boulevard
Batesville, Indiana
(Address of principal executive offices)

47006
(Zip Code)

Registrant's telephone number, including area code: **(812) 931-5000**

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions *see* General Instruction A.2. of Form 8-K):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Common Stock, without par value

Trading Symbol(s)
HI

Name of each exchange on which registered
New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01. Regulation FD Disclosure.

On March 31, 2025, Hillenbrand, Inc. (the “Company”) issued a press release announcing the closing of the previously announced sale of the majority ownership in the Company’s Milacron injection molding and extrusion business. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference.

Item 9.01 Financial Statements and Exhibits.

(d) *Exhibits.*

Exhibit No.	Description
Exhibit 99.1	Press Release, dated as of March 31, 2025, issued by the Company
Exhibit 104	Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 31, 2025

HILLENBRAND, INC.

BY: /s/ Nicholas R. Farrell

Nicholas R. Farrell
Senior Vice President, General Counsel, and Secretary

HILLENBRAND

Hillenbrand Completes Sale of Majority Stake in Milacron Injection Molding and Extrusion Business

- **Bain Capital now majority owner of Milacron**
- **Transaction enhances Hillenbrand's focus on core business**
- **Net proceeds to be used to reduce debt**

BATESVILLE, Ind., March 31, 2025 /PRNewswire/ -- Hillenbrand, Inc. (NYSE: HI) announced today that it has completed the previously announced sale of its majority interest in the Milacron injection molding and extrusion business ("Milacron"), within the Molding Technology Solutions segment, to Bain Capital for \$287 million, subject to agreed closing adjustments.

Bain Capital now owns an approximate 51% share and has full operational control of Milacron, while Hillenbrand maintains an ownership stake of approximately 49%. Bain Capital will provide greater focus and resources to help Milacron drive future growth and success, and the partnership with Bain Capital enables Hillenbrand to preserve the opportunity for future returns from Milacron.

"This transaction reflects the continued transformation of Hillenbrand's portfolio mix as a pure-play industrial company," said Kim Ryan, President and Chief Executive Officer of Hillenbrand. "We are confident it will deliver value to Hillenbrand and our shareholders by enhancing our overall margin profile, while enabling us to concentrate on growing our core process and automation equipment for the food, pharmaceutical, and polymer end markets. This partnership with Bain Capital positions Milacron for continued growth and success."

Following a strategic portfolio review, Hillenbrand announced its intention to sell a majority stake in Milacron. Hillenbrand acquired Milacron Holdings Corp. in 2019 in a transaction that included the Milacron injection molding and extrusion business, as well as Mold-Masters, DME, and Cimcool. Hillenbrand sold the Cimcool business in 2020 and retains ownership of the Mold-Masters and DME businesses.

"We look forward to supporting Milacron's experienced management team as they continue to enhance the company's global manufacturing and aftermarket solutions and capture opportunities presented by emerging technology and wider industry tailwinds," added Matt Evans, a Partner at Bain Capital. "Alongside our partners at Hillenbrand, we are excited to build on the company's strong legacy and leadership position by providing Milacron with the necessary tools, technology, and resources needed to accelerate its next phase of growth."

Following customary closing adjustments, Hillenbrand expects after tax net proceeds of approximately \$250 million, which will be used to pay down debt.

###

HILLENBRAND

About Hillenbrand

Hillenbrand (NYSE: HI) is a global industrial company that provides highly-engineered, mission-critical processing equipment and solutions to customers around the world. Our portfolio is composed of leading industrial brands that serve large, attractive end markets, including durable plastics, food, and recycling. Guided by our Purpose — Shape What Matters For Tomorrow™ — we pursue excellence, collaboration, and innovation to consistently shape solutions that best serve our people, our customers, and our communities. To learn more, visit: www.Hillenbrand.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements that are within the meaning of the Private Securities Litigation Reform Act of 1995 that are intended to be covered by the safe harbor provided thereunder, which reflect the current views of Bain Capital and Hillenbrand regarding future events, expectations, plans, and prospects for Milacron following the announced transaction. These statements are based on assumptions and involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied in such statements.

Forward-looking statements include, but are not limited to, statements regarding: the expected benefits of the transaction; Milacron's future growth, market position, and business strategy; anticipated industry trends, including implications with respect to growing supply chain resilience and domestic manufacturing.

Any number of factors, many of which are beyond Hillenbrand and Bain Capital's control, could cause Hillenbrand and Bain Capital's performance to differ significantly from what is described in the forward-looking statements. These factors include, but are not limited to: the ability to recognize the benefits of the divestiture, of the Milacron injection molding and extrusion business sale (the "Transaction"), including potential synergies and cost savings or the failure of Hillenbrand and Bain Capital, or the Transaction, to achieve its plans and objectives generally; any strategic and operational initiatives implemented by Bain Capital after the consummation of the Transaction; any failure by the parties to satisfy any conditions to the Transaction; potential adverse effects of the announcement or results of the Transaction on the market price of the Hillenbrand's common stock; and risks related to diversion of management's attention from Hillenbrand's ongoing business operations due to the Transaction.

Readers are urged to consider these risks and uncertainties in evaluating forward-looking statements and are cautioned not to place undue reliance on the forward-looking statements. For a more in-depth discussion of certain factors that could cause actual results to differ from those contained in forward-looking statements, see the discussions in Hillenbrand's filings with the U.S. Securities and Exchange Commission.

The forward-looking information in this release speaks only as of the date on which it is made. Hillenbrand and Bain Capital undertake no obligation to publicly update or revise any forward-looking statement, whether written or oral, made to reflect new information, future developments or otherwise.